vs

Side-by-side financial comparison of Brookfield Infrastructure Corp (BIPC) and Enovis CORP (ENOV). Click either name above to swap in a different company.

Brookfield Infrastructure Corp is the larger business by last-quarter revenue ($866.0M vs $548.9M, roughly 1.6× Enovis CORP). Brookfield Infrastructure Corp runs the higher net margin — -35.7% vs -104.1%, a 68.4% gap on every dollar of revenue. On growth, Enovis CORP posted the faster year-over-year revenue change (-2.2% vs -4.6%).

Brookfield Infrastructure Partners L.P. is a publicly traded limited partnership with corporate headquarters in Toronto, Canada, that engages in the acquisition and management of infrastructure assets on a global basis.

Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.

BIPC vs ENOV — Head-to-Head

Bigger by revenue
BIPC
BIPC
1.6× larger
BIPC
$866.0M
$548.9M
ENOV
Growing faster (revenue YoY)
ENOV
ENOV
+2.5% gap
ENOV
-2.2%
-4.6%
BIPC
Higher net margin
BIPC
BIPC
68.4% more per $
BIPC
-35.7%
-104.1%
ENOV

Income Statement — Q2 FY2025 vs Q3 FY2025

Metric
BIPC
BIPC
ENOV
ENOV
Revenue
$866.0M
$548.9M
Net Profit
$-309.0M
$-571.1M
Gross Margin
65.0%
59.9%
Operating Margin
62.7%
-101.7%
Net Margin
-35.7%
-104.1%
Revenue YoY
-4.6%
-2.2%
Net Profit YoY
-148.1%
18.8%
EPS (diluted)
$-9.99

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIPC
BIPC
ENOV
ENOV
Q4 25
$548.9M
Q3 25
$564.5M
Q2 25
$866.0M
$558.8M
Q4 24
$561.0M
Q3 24
$505.2M
Q2 24
$908.0M
$525.2M
Q1 24
$516.3M
Q4 23
$455.0M
Net Profit
BIPC
BIPC
ENOV
ENOV
Q4 25
$-571.1M
Q3 25
$-36.7M
Q2 25
$-309.0M
$-56.0M
Q4 24
$-703.2M
Q3 24
$-31.5M
Q2 24
$643.0M
$-18.6M
Q1 24
$-72.0M
Q4 23
$3.1M
Gross Margin
BIPC
BIPC
ENOV
ENOV
Q4 25
59.9%
Q3 25
59.3%
Q2 25
65.0%
59.5%
Q4 24
54.8%
Q3 24
56.7%
Q2 24
63.8%
55.0%
Q1 24
57.7%
Q4 23
58.1%
Operating Margin
BIPC
BIPC
ENOV
ENOV
Q4 25
-101.7%
Q3 25
-3.0%
Q2 25
62.7%
-8.4%
Q4 24
-118.5%
Q3 24
-6.3%
Q2 24
61.9%
-8.4%
Q1 24
-6.8%
Q4 23
-1.3%
Net Margin
BIPC
BIPC
ENOV
ENOV
Q4 25
-104.1%
Q3 25
-6.5%
Q2 25
-35.7%
-10.0%
Q4 24
-125.4%
Q3 24
-6.2%
Q2 24
70.8%
-3.5%
Q1 24
-13.9%
Q4 23
0.7%
EPS (diluted)
BIPC
BIPC
ENOV
ENOV
Q4 25
$-9.99
Q3 25
$-0.64
Q2 25
$-0.98
Q4 24
$-12.69
Q3 24
$-0.58
Q2 24
$-0.34
Q1 24
$-1.32
Q4 23
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIPC
BIPC
ENOV
ENOV
Cash + ST InvestmentsLiquidity on hand
$1.2B
$33.6M
Total DebtLower is stronger
$1.4B
Stockholders' EquityBook value
$2.2B
$2.0B
Total Assets
$23.9B
$4.4B
Debt / EquityLower = less leverage
0.67×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIPC
BIPC
ENOV
ENOV
Q4 25
$33.6M
Q3 25
$44.1M
Q2 25
$1.2B
$38.5M
Q4 24
$48.2M
Q3 24
$35.4M
Q2 24
$466.0M
$35.0M
Q1 24
$66.3M
Q4 23
$36.2M
Total Debt
BIPC
BIPC
ENOV
ENOV
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$1.4B
Q4 24
$1.3B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.3B
Q4 23
$466.2M
Stockholders' Equity
BIPC
BIPC
ENOV
ENOV
Q4 25
$2.0B
Q3 25
$2.6B
Q2 25
$2.2B
$2.6B
Q4 24
$2.6B
Q3 24
$3.3B
Q2 24
$3.5B
$3.3B
Q1 24
$3.3B
Q4 23
$3.4B
Total Assets
BIPC
BIPC
ENOV
ENOV
Q4 25
$4.4B
Q3 25
$5.0B
Q2 25
$23.9B
$4.9B
Q4 24
$4.7B
Q3 24
$5.6B
Q2 24
$23.7B
$5.4B
Q1 24
$5.5B
Q4 23
$4.5B
Debt / Equity
BIPC
BIPC
ENOV
ENOV
Q4 25
0.67×
Q3 25
0.54×
Q2 25
0.53×
Q4 24
0.52×
Q3 24
0.40×
Q2 24
0.41×
Q1 24
0.40×
Q4 23
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIPC
BIPC
ENOV
ENOV
Operating Cash FlowLast quarter
$478.0M
$82.6M
Free Cash FlowOCF − Capex
$29.1M
FCF MarginFCF / Revenue
5.3%
Capex IntensityCapex / Revenue
9.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$22.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIPC
BIPC
ENOV
ENOV
Q4 25
$82.6M
Q3 25
$47.8M
Q2 25
$478.0M
$-1.6M
Q4 24
$88.3M
Q3 24
$53.6M
Q2 24
$511.0M
$7.8M
Q1 24
$-36.2M
Q4 23
$68.4M
Free Cash Flow
BIPC
BIPC
ENOV
ENOV
Q4 25
$29.1M
Q3 25
$3.4M
Q2 25
$-44.9M
Q4 24
$35.1M
Q3 24
$2.4M
Q2 24
$-31.6M
Q1 24
$-73.1M
Q4 23
$40.5M
FCF Margin
BIPC
BIPC
ENOV
ENOV
Q4 25
5.3%
Q3 25
0.6%
Q2 25
-8.0%
Q4 24
6.3%
Q3 24
0.5%
Q2 24
-6.0%
Q1 24
-14.2%
Q4 23
8.9%
Capex Intensity
BIPC
BIPC
ENOV
ENOV
Q4 25
9.7%
Q3 25
7.9%
Q2 25
7.7%
Q4 24
9.5%
Q3 24
10.1%
Q2 24
7.5%
Q1 24
7.2%
Q4 23
6.1%
Cash Conversion
BIPC
BIPC
ENOV
ENOV
Q4 25
Q3 25
Q2 25
Q4 24
Q3 24
Q2 24
0.79×
Q1 24
Q4 23
22.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BIPC
BIPC

Segment breakdown not available.

ENOV
ENOV

Reconstructive Segment$258.0M47%
Surgical$129.0M23%
Prevention And Recovery$92.6M17%
Other Prevention And Recovery$71.4M13%

Related Comparisons